Literature DB >> 762412

In vitro activation of complement by isolated human heart subcellular membranes.

P C Giclas, R N Pinckard, M S Olson.   

Abstract

Activation of human complement (C) occurred in vitro when mitochondrial membranes isolated from normal human heart tissue were incubated with normal human serum. This activation, as measured by C3 depletion, was not completely inhibited by blocking classical pathway activity in serum treated with EGTA, in C2-deficient serum, or in C1-depleted serum, nor in serum heated at 50 degrees C for 30 min to block the alternative pathway, but it could be prevented by blocking the classical and the alternative pathway simultaneously with EDTA, or by treating heated serum (50 degrees C. 30 min) with EGTA. Factor B was converted in normal serum as well as in EGTA-treated serum, but not in EDTA-treated serum. Mitochondrial membranes had no direct enzymatic or other activity that could inactivate functionally or highly purified C4 or C3, but the membranes could bind and activate C1 either in serum or in functionally pure C1 preparations. C4 also bound to the mitochondrial membranes only in the presence of C1. These data suggest that the activation of C by heart subcellular membranes involved both the classical and the alternative pathways, that the mitochondrial membrane preparations were capable of forming stabel complexes with C1 and C4, but not C3, and that the mitochondrial membrane preparations did not contain enzymes or have inherent properties that could directly cause C3 conversion.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762412

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Complement activation promotes muscle inflammation during modified muscle use.

Authors:  J Frenette; B Cai; J G Tidball
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Complement and contact activation in term neonates after fetal acidosis.

Authors:  J Sonntag; M H Wagner; E Strauss; M Obladen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-03       Impact factor: 5.747

3.  The erythrocyte as instigator of inflammation. Generation of amidated C3 by erythrocyte adenosine deaminase.

Authors:  M K Hostetter; G M Johnson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  The acute phase response of C3, C5, ceruloplasmin, and C-reactive protein induced by turpentine pleurisy in the rabbit.

Authors:  P C Giclas; U Manthei; R C Strunk
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

5.  Fibronectin binds to the C1q component of complement.

Authors:  D H Bing; S Almeda; H Isliker; J Lahav; R O Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

6.  Complement fragments, alveolar macrophages, and alveolitis.

Authors:  P M Henson; K McCarthy; G L Larsen; R O Webster; P C Giclas; R B Dreisin; T E King; J O Shaw
Journal:  Am J Pathol       Date:  1979-10       Impact factor: 4.307

7.  Activation of complement by cells infected with respiratory syncytial virus.

Authors:  T F Smith; K McIntosh; M Fishaut; P M Henson
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

8.  Fibronectin binding to complement subcomponent C1q. Localization of their respective binding sites.

Authors:  J Sorvillo; I Gigli; E Pearlstein
Journal:  Biochem J       Date:  1985-02-15       Impact factor: 3.857

9.  Complement localization and mediation of ischemic injury in baboon myocardium.

Authors:  R N Pinckard; R A O'Rourke; M H Crawford; F S Grover; L M McManus; J J Ghidoni; S B Storrs; M S Olson
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

10.  Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia.

Authors:  Anne M Lynch; James R Murphy; Tim Byers; Ronald S Gibbs; Margaret C Neville; Patricia C Giclas; Jane E Salmon; V Michael Holers
Journal:  Am J Obstet Gynecol       Date:  2008-01-25       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.